Search
Fate Therapeutics Inc
FATEAdd to Watchlist
2.090USD
+0.130+6.63%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
243.61MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Fate Therapeutics Inc is 7.50, ranking 289 out of 389 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 8.00 and a low of 2.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
5.588
Target Price
+167.34%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
65
Total
4
Median
6
Average
Company name
Ratings
Analysts
Fate Therapeutics Inc
FATE
12
Apple Inc
AAPL
48
Ge Vernova Inc
GEV
37
Tapestry Inc
TPR
24
Verisk Analytics Inc
VRSK
20
Avantor Inc
AVTR
19
1
2
3
...
13
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Fate Therapeutics Inc's expected revenue for the next quarter?
Fate Therapeutics Inc's expected revenue is 1.04M.
What is Fate Therapeutics Inc's price target?
Analysts forecast that Fate Therapeutics Inc's price target is USD 5.00, with the highest forecast at USD 8.00 and the lowest forecast at USD 2.00.
How have Fate Therapeutics IncFATE's recent earnings per share performed?
The market expectation was USD -0.26, while Fate Therapeutics IncFATE's earnings per share (EPS) for the previous quarter was USD -0.27. EPS for the next quarter is expected at USD -0.27.
What is the analyst rating for Fate Therapeutics Inc?
Based on the ratings of Fate Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
